Ratings by Rothschild Redburn (Qize Ding)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/1/2026 | Apogee Therapeutics Inc | APGE | New Coverage | Buy (N/A) |
82.03 (135.08) |
64.67% | Details | |
| 3/19/2026 | Moonlake Immunotherapeutics | MLTX | Upgrade | Buy (Neutral) |
16.77 (15.13) |
-9.78% | Details | |
| 2/12/2026 | Arcellx Inc. | ACLX | Downgrade | Neutral (Buy) |
67.24 (115.07) |
71.13% | Details | |
| 2/12/2026 | Legend Biotech Corp. | LEGN | Downgrade | Neutral (Buy) |
17.91 (21.13) |
17.98% | Details | |
| 12/4/2025 | Insmed | INSM | New Coverage | Buy (N/A) |
206.60 (121.51) |
-41.19% | Details | |
| 7/28/2025 | Moonlake Immunotherapeutics | MLTX | New Coverage | Neutral (N/A) |
55.07 (16.77) |
-69.55% | Details | |
| 10/8/2024 | Legend Biotech Corp. | LEGN | New Coverage | Buy (N/A) |
49.07 (17.91) |
-63.5% | Details | |
| 10/8/2024 | Arcellx Inc. | ACLX | New Coverage | Buy (N/A) |
78.23 (67.24) |
-14.05% | Details |
